Global Hematologic Malignancies Testing Market: Focus on Product, Disease, Technology, End User, Region/Country Data and Competitive Landscape – Analysis and Forecast, 2019-2025
Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.
Key Questions Answered in this Report:
The hematologic malignancies testing industry analysis by BIS Research projects the market to grow at a significant CAGR of 15.24% during the forecast period, 2019-2025. The hematologic malignancies testing market generated $1,754.8 million revenue in 2018, in terms of value.
The hematologic malignancies testing market growth has been primarily attributed to the major drivers in this market such as rising incidence of hematologic malignancies, increasing adoption of inorganic growth strategies in the market, favorable reimbursement scenario in the global hematologic malignancies testing market, and increasing funding in hematologic malignancies testing market. However, there are significant challenges which are restraining the market growth. These challenges include high pricing pressure, lack of trained professionals, and issues pertaining to the analytical validity of genetic testing for cancers.
Expert Quote
“The development of specialized kits has achieved huge success over the past year with NGS and FISH based kits now available across major regions proving the potential to screen malignancies at an early stage.”
Scope of the Market Intelligence on Hematologic Malignancies Testing Market
The hematologic malignancies testing market report provides a holistic view of the market in terms of various factors influencing it, including product optimization, and technological advancements.
The scope of this report is centered upon conducting a detailed study of the products and manufacturers allied with the market. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, growth potential of each underlying sub-segment, and company, as well as other vital information with respect to global hematologic malignancies testing market.
Market Segmentation
The hematologic malignancies testing market segmentation (on the basis of product) is further segmented into kits and services.
The hematologic malignancies testing market segmentation (on the basis of disease) is segmented into leukemia, lymphoma, multiple myeloma, myeloproliferative neoplasms, and myelodysplastic syndromes.
The hematologic malignancies testing market segmentation (on the basis of technology) is segmented into next-generation sequencing (NGS), polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), immunohistochemistry (IHC).
The hematologic malignancies testing market segmentation (on the basis of end user) is segmented into specialty clinics and hospitals, diagnostic laboratories, reference laboratories, and research institutions.
Key Companies in the Hematologic Malignancies Testing Market
The key manufacturers who have been contributing significantly to the Hematologic malignancies testing market include Abbott Laboratories, Adaptive Biotechnologies, ArcherDX, Inc., ARUP Laboratories, ASURAGEN, INC., Bio-Rad Laboratories, Inc., Cancer Genetics Inc., Sysmex Corporation, F. Hoffmann-La Roche AG, Illumina, Inc, Invivoscribe, Inc., Invitae Corporation, ICON plc, NeoGenomics Laboratories, Inc., and QIAGEN N.V., among others.
Key Questions Answered in this Report:
- What are the major market drivers, challenges, and opportunities in the global hematologic malignancies testing market?
- What are the underlying structures resulting in the emerging trends within the global hematologic malignancies testing market?
- How is each segment expected to grow in the global hematologic malignancies testing market during the forecast period and what is the estimated revenue to be generated by each of the segments by the end of 2025?
- What are the key developmental strategies which are implemented by the major players in order to sustain in the competitive market? What are the key regulatory implications in developed and developing regions for hematologic malignancies testing?
- Who are the leading players with significant offerings to the global hematologic malignancies testing market? What is the current market dominance for each of these leading players?
- What would be the compound growth rate witnessed by the leading players in the market during the forecast period 2019-2025?
- What are the key applications in global hematologic malignancies testing market? What are the major segments of these applications?
- Which are the dominant disease areas of the global hematologic malignancies testing market? Which is the fastest growing disease area in the global hematologic malignancies testing market?
- Who are the key manufacturers and service providers in the global hematologic malignancies testing market, and what are their contributions? What is the growth potential of each major hematologic malignancies testing solution provider?
- What is the scope of the global hematologic malignancies testing market in North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa?
The hematologic malignancies testing industry analysis by BIS Research projects the market to grow at a significant CAGR of 15.24% during the forecast period, 2019-2025. The hematologic malignancies testing market generated $1,754.8 million revenue in 2018, in terms of value.
The hematologic malignancies testing market growth has been primarily attributed to the major drivers in this market such as rising incidence of hematologic malignancies, increasing adoption of inorganic growth strategies in the market, favorable reimbursement scenario in the global hematologic malignancies testing market, and increasing funding in hematologic malignancies testing market. However, there are significant challenges which are restraining the market growth. These challenges include high pricing pressure, lack of trained professionals, and issues pertaining to the analytical validity of genetic testing for cancers.
Expert Quote
“The development of specialized kits has achieved huge success over the past year with NGS and FISH based kits now available across major regions proving the potential to screen malignancies at an early stage.”
Scope of the Market Intelligence on Hematologic Malignancies Testing Market
The hematologic malignancies testing market report provides a holistic view of the market in terms of various factors influencing it, including product optimization, and technological advancements.
The scope of this report is centered upon conducting a detailed study of the products and manufacturers allied with the market. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, growth potential of each underlying sub-segment, and company, as well as other vital information with respect to global hematologic malignancies testing market.
Market Segmentation
The hematologic malignancies testing market segmentation (on the basis of product) is further segmented into kits and services.
The hematologic malignancies testing market segmentation (on the basis of disease) is segmented into leukemia, lymphoma, multiple myeloma, myeloproliferative neoplasms, and myelodysplastic syndromes.
The hematologic malignancies testing market segmentation (on the basis of technology) is segmented into next-generation sequencing (NGS), polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), immunohistochemistry (IHC).
The hematologic malignancies testing market segmentation (on the basis of end user) is segmented into specialty clinics and hospitals, diagnostic laboratories, reference laboratories, and research institutions.
Key Companies in the Hematologic Malignancies Testing Market
The key manufacturers who have been contributing significantly to the Hematologic malignancies testing market include Abbott Laboratories, Adaptive Biotechnologies, ArcherDX, Inc., ARUP Laboratories, ASURAGEN, INC., Bio-Rad Laboratories, Inc., Cancer Genetics Inc., Sysmex Corporation, F. Hoffmann-La Roche AG, Illumina, Inc, Invivoscribe, Inc., Invitae Corporation, ICON plc, NeoGenomics Laboratories, Inc., and QIAGEN N.V., among others.
EXECUTIVE SUMMARY
1 MARKET OVERVIEW
1.1 Introduction
1.2 Historical Perspective
1.3 Types of Hematologic Malignancy Diagnostic Tests
1.4 Global Footprint
1.5 Trends and Future Potential
2 MARKET DYNAMICS
2.1 Market Drivers
2.1.1 Rising Incidence of Hematologic Malignancies
2.1.2 Increasing Adoption of Inorganic Growth Strategies in the Market
2.1.3 Favorable Reimbursement Scenario in the Global Hematologic Malignancies Testing Market
2.1.4 Increase in Funding in Hematologic Malignancies Testing Market
2.2 Restraints
2.2.1 High Pricing Pressure
2.2.2 Lack of Trained Professionals
2.2.3 Issues Pertaining to the Analytical Validity of Genetic Testing for Cancers
2.3 Market Opportunities
2.3.1 Opportunities in the Emerging Economies
2.3.2 Technological Advancements in the Field of Molecular Diagnostics
3 COMPETITIVE LANDSCAPE
3.1 Key Strategies and Developments
3.1.1 Synergistic Activities
3.1.2 Approvals
3.1.3 Product Launches and Enhancements
3.1.4 Acquisitions
3.1.5 Expansion Activities
3.2 Product Scenario
3.3 Funding Scenario
3.4 Market Share Analysis
3.5 Growth Share Analysis (Opportunity Mapping)
3.5.1 By Company
3.5.2 By Region
3.5.3 By Product
3.6 Comprehensive Competitive Index
4 INDUSTRY INSIGHTS
4.1 Regulatory Framework
4.1.1 Legal Requirements and Framework in the U.S.
4.1.2 Legal Requirements and Framework in Europe
4.1.3 Legal Requirements and Framework in Asia-Pacific
4.1.3.1 Japan
4.1.3.2 China
4.2 Reimbursement Scenario
4.3 Physicians’ Perceptions
5 GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET (BY PRODUCT)
5.1 Services
5.2 Kits
5.2.1 Gene Panels
5.2.2 Molecular Clonality Testing
5.2.3 Translocation Testing
5.2.4 Mutation Testing
5.2.5 Minimal Residual Disease (MRD) Testing
6 GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET (BY DISEASE)
6.1 Leukemia
6.2 Lymphoma
6.3 Multiple Myeloma
6.4 Myeloproliferative Neoplasms
6.5 Myelodysplastic Syndromes
7 GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET (BY TECHNOLOGY)
7.1 Next-Generation Sequencing (NGS)
7.2 Polymerase Chain Reaction (PCR)
7.3 Fluorescence in Situ Hybridization (FISH)
7.4 Immunohistochemistry (IHC)
7.5 Flow Cytometry
7.6 Other Technologies
8 GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET (BY END USER)
8.1 Specialty Clinics and Hospitals
8.2 Diagnostic Laboratories
8.3 Reference Laboratories
8.4 Research Institutions
9 GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET (BY REGION)
9.1 Overview
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 U.K.
9.3.3 France
9.3.4 Italy
9.3.5 Spain
9.3.6 Rest-of-Europe
9.4 Asia-Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 Singapore
9.4.6 Rest-of-APAC
9.5 Rest-of-the-World
9.5.1 Latin America
9.5.2 Middle East and Africa
10 COMPANY PROFILES
10.1 Overview
10.2 Abbott Laboratories
10.2.1 Company Overview
10.2.2 Role of Abbott Laboratories in the Global Hematologic Malignancies Testing Market
10.2.3 Financials
10.2.4 Key Insights About Financial Health of the Company
10.2.5 SWOT Analysis
10.3 Illumina, Inc.
10.3.1 Company Overview
10.3.2 Role of Illumina, Inc. in the Global Hematologic Malignancies Testing Market
10.3.3 Financials
10.3.4 Key Insights About Financial Health of the Company
10.3.5 SWOT Analysis
10.4 F. Hoffmann-La Roche Ltd
10.4.1 Company Overview
10.4.2 Role of F. Hoffmann-La Roche Ltd in the Global Hematologic Malignancies Testing Market
10.4.3 Financials
10.4.4 Key Insights About Financial Health of the Company
10.4.5 SWOT Analysis
10.5 Bio-Rad Laboratories, Inc.
10.5.1 Company Overview
10.5.2 Role of Bio-Rad Laboratories, Inc. in the Global Hematologic Malignancies Testing Market
10.5.3 Financials
10.5.4 Key Insights About Financial Health of the Company
10.5.5 SWOT Analysis
10.6 Sysmex Corporation
10.6.1 Company Overview
10.6.2 Role of Sysmex Corporation in the Global Hematologic Malignancies Testing Market
10.6.3 Financials
10.6.4 Key Insights About Financial Health of the Company
10.6.5 SWOT Analysis
10.7 ASURAGEN, INC.
10.7.1 Company Overview
10.7.2 Role of ASURAGEN, INC. in the Global Hematologic Malignancies Testing Market
10.7.3 SWOT Analysis
10.8 Cancer Genetics Inc.
10.8.1 Company Overview
10.8.2 Role of Cancer Genetics Inc.in the Global Hematologic Malignancies Testing Market
10.8.3 Financials
10.8.4 Key Insights About Financial Health of the Company
10.8.5 SWOT Analysis
10.9 QIAGEN N.V.
10.9.1 Company Overview
10.9.2 Role of QIAGEN N.V. in the Global Hematologic Malignancies Testing Market
10.9.3 Financials
10.9.4 Key Insights about Financial Health of the Company
10.9.5 SWOT Analysis
10.10 ArcherDX, Inc.
10.10.1 Company Overview
10.10.2 Role of ArcherDX, Inc. in the Global Hematologic Malignancies Testing Market
10.10.3 SWOT Analysis
10.11 Adaptive Biotechnologies
10.11.1 Company Overview
10.11.2 Role of Adaptive Biotechnologies in the Global Hematologic Malignancies Testing Market
10.11.3 SWOT Analysis
10.12 ICON plc
10.12.1 Company Overview
10.12.2 Role of ICON plc in the Global Hematologic Malignancies Testing Market
10.12.3 Financials
10.12.4 SWOT Analysis
10.13 Quest Diagnostics Incorporated
10.13.1 Company Overview
10.13.2 Role of Quest Diagnostics Limited in the Global Hematologic Malignancies Testing Market
10.13.3 Financials
10.13.4 SWOT Analysis
10.14 ARUP Laboratories
10.14.1 Company Overview
10.14.2 Role of ARUP Laboratories in the Global Hematologic Malignancies Testing Market
10.14.3 SWOT Analysis
10.15 Invivoscribe, Inc.
10.15.1 Company Overview
10.15.2 Role of Invivoscribe, Inc. in the Global Hematologic Malignancies Testing Market
10.15.3 SWOT Analysis
10.16 NeoGenomics Laboratories, Inc.
10.16.1 Company Overview
10.16.2 Role of NeoGenomics Laboratories, Inc. in the hematologic malignancies testing Market
10.16.3 Financials
10.16.4 Key Insights about Financial Health of the Company
10.16.5 SWOT Analysis
11 RESEARCH SCOPE AND METHODOLOGY
11.1 Scope of the Study
11.2 Research Methodology
11.3 Data Sources
11.4 Assumptions and Limitations
11.5 Data and Prediction Modeling
1 MARKET OVERVIEW
1.1 Introduction
1.2 Historical Perspective
1.3 Types of Hematologic Malignancy Diagnostic Tests
1.4 Global Footprint
1.5 Trends and Future Potential
2 MARKET DYNAMICS
2.1 Market Drivers
2.1.1 Rising Incidence of Hematologic Malignancies
2.1.2 Increasing Adoption of Inorganic Growth Strategies in the Market
2.1.3 Favorable Reimbursement Scenario in the Global Hematologic Malignancies Testing Market
2.1.4 Increase in Funding in Hematologic Malignancies Testing Market
2.2 Restraints
2.2.1 High Pricing Pressure
2.2.2 Lack of Trained Professionals
2.2.3 Issues Pertaining to the Analytical Validity of Genetic Testing for Cancers
2.3 Market Opportunities
2.3.1 Opportunities in the Emerging Economies
2.3.2 Technological Advancements in the Field of Molecular Diagnostics
3 COMPETITIVE LANDSCAPE
3.1 Key Strategies and Developments
3.1.1 Synergistic Activities
3.1.2 Approvals
3.1.3 Product Launches and Enhancements
3.1.4 Acquisitions
3.1.5 Expansion Activities
3.2 Product Scenario
3.3 Funding Scenario
3.4 Market Share Analysis
3.5 Growth Share Analysis (Opportunity Mapping)
3.5.1 By Company
3.5.2 By Region
3.5.3 By Product
3.6 Comprehensive Competitive Index
4 INDUSTRY INSIGHTS
4.1 Regulatory Framework
4.1.1 Legal Requirements and Framework in the U.S.
4.1.2 Legal Requirements and Framework in Europe
4.1.3 Legal Requirements and Framework in Asia-Pacific
4.1.3.1 Japan
4.1.3.2 China
4.2 Reimbursement Scenario
4.3 Physicians’ Perceptions
5 GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET (BY PRODUCT)
5.1 Services
5.2 Kits
5.2.1 Gene Panels
5.2.2 Molecular Clonality Testing
5.2.3 Translocation Testing
5.2.4 Mutation Testing
5.2.5 Minimal Residual Disease (MRD) Testing
6 GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET (BY DISEASE)
6.1 Leukemia
6.2 Lymphoma
6.3 Multiple Myeloma
6.4 Myeloproliferative Neoplasms
6.5 Myelodysplastic Syndromes
7 GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET (BY TECHNOLOGY)
7.1 Next-Generation Sequencing (NGS)
7.2 Polymerase Chain Reaction (PCR)
7.3 Fluorescence in Situ Hybridization (FISH)
7.4 Immunohistochemistry (IHC)
7.5 Flow Cytometry
7.6 Other Technologies
8 GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET (BY END USER)
8.1 Specialty Clinics and Hospitals
8.2 Diagnostic Laboratories
8.3 Reference Laboratories
8.4 Research Institutions
9 GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET (BY REGION)
9.1 Overview
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 U.K.
9.3.3 France
9.3.4 Italy
9.3.5 Spain
9.3.6 Rest-of-Europe
9.4 Asia-Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 Singapore
9.4.6 Rest-of-APAC
9.5 Rest-of-the-World
9.5.1 Latin America
9.5.2 Middle East and Africa
10 COMPANY PROFILES
10.1 Overview
10.2 Abbott Laboratories
10.2.1 Company Overview
10.2.2 Role of Abbott Laboratories in the Global Hematologic Malignancies Testing Market
10.2.3 Financials
10.2.4 Key Insights About Financial Health of the Company
10.2.5 SWOT Analysis
10.3 Illumina, Inc.
10.3.1 Company Overview
10.3.2 Role of Illumina, Inc. in the Global Hematologic Malignancies Testing Market
10.3.3 Financials
10.3.4 Key Insights About Financial Health of the Company
10.3.5 SWOT Analysis
10.4 F. Hoffmann-La Roche Ltd
10.4.1 Company Overview
10.4.2 Role of F. Hoffmann-La Roche Ltd in the Global Hematologic Malignancies Testing Market
10.4.3 Financials
10.4.4 Key Insights About Financial Health of the Company
10.4.5 SWOT Analysis
10.5 Bio-Rad Laboratories, Inc.
10.5.1 Company Overview
10.5.2 Role of Bio-Rad Laboratories, Inc. in the Global Hematologic Malignancies Testing Market
10.5.3 Financials
10.5.4 Key Insights About Financial Health of the Company
10.5.5 SWOT Analysis
10.6 Sysmex Corporation
10.6.1 Company Overview
10.6.2 Role of Sysmex Corporation in the Global Hematologic Malignancies Testing Market
10.6.3 Financials
10.6.4 Key Insights About Financial Health of the Company
10.6.5 SWOT Analysis
10.7 ASURAGEN, INC.
10.7.1 Company Overview
10.7.2 Role of ASURAGEN, INC. in the Global Hematologic Malignancies Testing Market
10.7.3 SWOT Analysis
10.8 Cancer Genetics Inc.
10.8.1 Company Overview
10.8.2 Role of Cancer Genetics Inc.in the Global Hematologic Malignancies Testing Market
10.8.3 Financials
10.8.4 Key Insights About Financial Health of the Company
10.8.5 SWOT Analysis
10.9 QIAGEN N.V.
10.9.1 Company Overview
10.9.2 Role of QIAGEN N.V. in the Global Hematologic Malignancies Testing Market
10.9.3 Financials
10.9.4 Key Insights about Financial Health of the Company
10.9.5 SWOT Analysis
10.10 ArcherDX, Inc.
10.10.1 Company Overview
10.10.2 Role of ArcherDX, Inc. in the Global Hematologic Malignancies Testing Market
10.10.3 SWOT Analysis
10.11 Adaptive Biotechnologies
10.11.1 Company Overview
10.11.2 Role of Adaptive Biotechnologies in the Global Hematologic Malignancies Testing Market
10.11.3 SWOT Analysis
10.12 ICON plc
10.12.1 Company Overview
10.12.2 Role of ICON plc in the Global Hematologic Malignancies Testing Market
10.12.3 Financials
10.12.4 SWOT Analysis
10.13 Quest Diagnostics Incorporated
10.13.1 Company Overview
10.13.2 Role of Quest Diagnostics Limited in the Global Hematologic Malignancies Testing Market
10.13.3 Financials
10.13.4 SWOT Analysis
10.14 ARUP Laboratories
10.14.1 Company Overview
10.14.2 Role of ARUP Laboratories in the Global Hematologic Malignancies Testing Market
10.14.3 SWOT Analysis
10.15 Invivoscribe, Inc.
10.15.1 Company Overview
10.15.2 Role of Invivoscribe, Inc. in the Global Hematologic Malignancies Testing Market
10.15.3 SWOT Analysis
10.16 NeoGenomics Laboratories, Inc.
10.16.1 Company Overview
10.16.2 Role of NeoGenomics Laboratories, Inc. in the hematologic malignancies testing Market
10.16.3 Financials
10.16.4 Key Insights about Financial Health of the Company
10.16.5 SWOT Analysis
11 RESEARCH SCOPE AND METHODOLOGY
11.1 Scope of the Study
11.2 Research Methodology
11.3 Data Sources
11.4 Assumptions and Limitations
11.5 Data and Prediction Modeling
LIST OF TABLES
Table 1.1: Global Hematologic Malignancies Testing Market, by Region, 2018-2025 ($Million)
Table 3.1: Market Players with Key Product Listing
Table 4.1: Registration Criteria for IVD Medical Devices as per the CFDA
Table 4.2: Key Coverage Providers for Hematologic Malignancies Testing
Table 1.1: Global Hematologic Malignancies Testing Market, by Region, 2018-2025 ($Million)
Table 3.1: Market Players with Key Product Listing
Table 4.1: Registration Criteria for IVD Medical Devices as per the CFDA
Table 4.2: Key Coverage Providers for Hematologic Malignancies Testing
LIST OF FIGURES
Figure 1: Impact Analysis on the Global Hematologic Malignancies Testing Market
Figure 2: Hematologic Malignancies Testing Market, By Product, 2018 vs. 2025 ($Million)
Figure 3: Hematologic Malignancies Testing Market, By Disease, 2018 vs. 2025 ($Million)
Figure 4: Hematologic Malignancies Testing Market, By End User, 2018 vs. 2025 ($Million)
Figure 5: Global Hematologic Malignancies Testing Market Snapshot
Figure 1.1: Global Hematologic Malignancies Testing Market, 2018-2025 ($Million)
Figure 2.1: Market Dynamics of Global Hematologic Malignancies Testing Market
Figure 2.2: Leukemia, U.S. Incident Rates per 100,000, 2006-2015
Figure 3.1: Share of Key Developments and Strategies, January 2016 – September 2019
Figure 3.2: Synergistic Activities Share (by Companies), January 2016 – September 2019
Figure 3.3: Approvals Share (by Companies), January 2016 – September 2019
Figure 3.4: Product Launches and Enhancements Share (by Companies), January 2016 – September 2019
Figure 3.5: Acquisition and Merger Share (by Companies), January 2016 – September 2019
Figure 3.6: Market Share Analysis for the Global Hematologic Malignancies Testing Market, 2018
Figure 3.7: Growth Share Matrix for Global Hematologic Malignancies Testing Market (by company), 2018
Figure 3.8: Growth Share Matrix for Global Hematologic Malignancies Testing Market (by region), 2018
Figure 3.9: Growth Share Matrix for Global Hematologic Malignancies Testing Market (by Product), 2018
Figure 3.10: Comprehensive Competitive Index, 2018 (by Region)
Figure 5.1: Global Hematologic Malignancies Testing Market (by Product), 2019 vs 2025
Figure 5.2: Hematologic Malignancies Testing Services Market, $Million, 2018-2025
Figure 5.3: Hematologic Malignancies Testing Kits Market, $Million, 2018-2025
Figure 5.4: Gene Panels Market, $Million, 2018-2025
Figure 5.5: Molecular Clonality Testing Market, $Million, 2018-2025
Figure 5.6: Translocation Testing Market, $Million, 2018-2025
Figure 5.7: Mutation Testing Market, $Million, 2018-2025
Figure 5.8: Minimal Residual Disease (MRD) Testing Market, $Million, 2018-2025
Figure 6.1: Global Hematologic Malignancies Testing Market (by Disease), 2019 vs 2025
Figure 6.2: Leukemia Testing Market, $Million, 2018-2025
Figure 6.3: Lymphoma Testing Market, $Million, 2018-2025
Figure 6.4: Multiple Myeloma Testing Market, $Million, 2018-2025
Figure 6.5: Myeloproliferative Neoplasms Testing Market, $Million, 2018-2025
Figure 6.6: Myelodysplastic Syndromes Testing Market, $Million, 2018-2025
Figure 7.1: Global Hematologic Malignancies Testing Market (by Technology), 2019 vs 2025
Figure 7.2: Hematologic Malignancies Testing Market by NGS, $Million, 2018-2025
Figure 7.3: Hematologic Malignancies Testing Market by PCR, $Million, 2018-2025
Figure 7.4: Hematologic Malignancies Testing Market by FISH, $Million, 2018-2025
Figure 7.5: Hematologic Malignancies Testing Market by Immunohistochemistry, $Million, 2018-2025
Figure 7.6: Hematologic Malignancies Testing Market by Flow Cytometry, $Million, 2018-2025
Figure 7.7: Hematologic Malignancies Testing Market by Other Technologies, $Million, 2018-2025
Figure 8.1: Global Hematologic Malignancies Testing Market (by End User), 2019 vs 2025
Figure 8.2: Specialty Clinics and Hospitals Market, $Million, 2018-2025
Figure 8.3: Diagnostic Laboratories Market, $Million, 2018-2025
Figure 8.4: Reference Laboratories Market, $Million, 2018-2025
Figure 8.5: Research Institutions Market, $Million, 2018-2025
Figure 9.1: Hematologic Malignancies Testing Market (by Region), $Million, 2019 and 2025
Figure 9.2: North America: Market Dynamics
Figure 9.3: North America Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.4: North America Hematologic Malignancies Testing Market (by Country), $Million, 2019 vs 2025
Figure 9.5: U.S. Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.6: Canada Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.7: Europe: Market Dynamics
Figure 9.8: Europe Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.9: Europe Hematologic Malignancies Testing Market (by Country), $Million, 2019 vs 2025
Figure 9.10: Germany Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.11: U.K. Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.12: France Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.13: Italy Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.14: Spain Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.15: Rest-of-Europe Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.16: Asia-Pacific: Market Dynamics
Figure 9.17: Asia-Pacific Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.18: Asia-Pacific Hematologic Malignancies Testing Market (by Country), $Million, 2019 vs 2025
Figure 9.19: China Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.20: Japan Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.21: India Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.22: Number of Death in India, by Leukemia (2010-2017)
Figure 9.23: Australia Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.24: Number of Death in Australia, by Leukemia (2010-2017)
Figure 9.25: Singapore Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.26: Rest-of-APAC Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.27: Rest-of-the-World: Market Dynamics
Figure 9.28: Rest-of-the-World Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.29: Rest-of-the-World Hematologic Malignancies Testing Market (by Country), $Million, 2019 vs 2025
Figure 9.30: Latin America Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.31: Middle East and Africa Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.32: Cancer Deaths in Saudi Arabia, By Type (2010-2016)
Figure 10.1: Total Number of Companies Profiled
Figure 10.2: Abbott Laboratories: Overall Product Portfolio
Figure 10.3: Abbott Laboratories: Overall Financials, 2016-2018
Figure 10.4: Abbott Laboratories: Revenue (by Segment), 2016-2018
Figure 10.5: Abbott Laboratories: Revenue Split for Diagnostics, 2016-2018
Figure 10.6: Abbott Laboratories: Revenue (by Region), 2016-2018
Figure 10.7: Abbott Laboratories: R&D Expenditure, 2016-2018
Figure 10.8: Abbott Laboratories: SWOT Analysis
Figure 10.9: Illumina, Inc.: Overall Product Portfolio
Figure 10.10: Illumina, Inc.: Overall Financials, 2016-2018
Figure 10.11: Illumina, Inc.: Revenue (by Segment), 2016-2018
Figure 10.12: Illumina, Inc.: Revenue (by Region), 2016-2018
Figure 10.13: Illumina, Inc.: R&D Expenditure, 2016-2018
Figure 10.14: Illumina, Inc.: SWOT Analysis
Figure 10.15: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
Figure 10.16: F. Hoffmann-La Roche Ltd: Overall Financials, 2016-2018
Figure 10.17: F. Hoffmann-La Roche Ltd: Sales (by Segment), 2016-2018
Figure 10.18: F. Hoffmann-La Roche Ltd: Sales (by Region), 2016-2018
Figure 10.19: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2016-2018
Figure 10.20: F. Hoffmann-La Roche: SWOT Analysis
Figure 10.21: Bio-Rad Laboratories, Inc.: Product Portfolio
Figure 10.22: Bio-Rad Laboratories, Inc.: Overall Financials, 2016-2018
Figure 10.23: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2016-2018
Figure 10.24: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2016-2018
Figure 10.25: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2016-2018
Figure 10.26: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 10.27: Sysmex Corporation: Overall Product Portfolio
Figure 10.28: Sysmex Corporation: Overall Financials, 2016-2018
Figure 10.29: Sysmex Corporation: Sales (by Segment), 2016-2018
Figure 10.30: Sysmex Corporation: Sales (by Region), 2016-2018
Figure 10.31: Sysmex Corporation: R&D Expenditure, 2016-2018
Figure 10.32: Sysmex Corporation: SWOT Analysis
Figure 10.33: ASURAGEN, INC.: Overall Product Portfolio
Figure 10.34: ASURAGEN, INC.: SWOT Analysis
Figure 10.35: Product Portfolio: Cancer Genetics Inc.
Figure 10.36: Cancer Genetics Inc.: Overall Financials, 2016-2018
Figure 10.37: Cancer Genetics Inc.: Sales (by Segment), 2016-2018
Figure 10.38: Cancer Genetics Inc.: Sales (by Region), 2016-2018
Figure 10.39: Cancer Genetics Inc.: R&D Expenditure, 2016-2018
Figure 10.40: Cancer Genetics Inc.: SWOT Analysis
Figure 10.41: QIAGEN N.V.: Overall Product Portfolio
Figure 10.42: QIAGEN N.V.: Overall Financials, 2016-2018
Figure 10.43: QIAGEN N.V.: Revenue (by Segment), 2016-2018
Figure 10.44: QIAGEN N.V.: Revenue (by Region), 2016-2018
Figure 10.45: QIAGEN N.V.: R&D Expenditure, 2016-2018
Figure 10.46: QIAGEN N.V.: SWOT Analysis
Figure 10.47: ArcherDX, Inc.: Overall Product Portfolio
Figure 10.48: ArcherDX, Inc.: SWOT Analysis
Figure 10.49: Adaptive Biotechnologies: Overall Product Portfolio
Figure 10.50: Adaptive Biotechnologies: SWOT Analysis
Figure 10.51: ICON plc: Overall Product Portfolio
Figure 10.52: ICON plc: Overall Financials, 2016-2018
Figure 10.53: ICON plc: Revenue (by Region), 2016-2018
Figure 10.54: ICON plc: SWOT Analysis
Figure 10.55: Quest Diagnostics Incorporated: Overall Product Portfolio
Figure 10.56: Quest Diagnostics Incorporated: Overall Financials, 2016-2018
Figure 10.57: Quest Diagnostics Incorporated: Revenue (by Business Segment), 2016-2018
Figure 10.58: Quest Diagnostics Incorporated: SWOT Analysis
Figure 10.59: ARUP Laboratories: Overall Product Portfolio
Figure 10.60: ARUP Laboratories: SWOT Analysis
Figure 10.61: Invivoscribe, Inc.: Overall Product Portfolio
Figure 10.62: Invivoscribe, Inc.: SWOT Analysis
Figure 10.63: NeoGenomics Laboratories, Inc.: Overall Product Portfolio
Figure 10.64: NeoGenomics Laboratories, Inc.: Overall Financials, 2016-2018
Figure 10.65: NeoGenomics Laboratories, Inc.: Revenue (by Segment), 2016-2018
Figure 10.66: NeoGenomics Laboratories, Inc.: R&D Expenditure, 2016-2018
Figure 10.67: NeoGenomics Laboratories, Inc.: SWOT Analysis
Figure 11.1: Global Hematologic Malignancies Testing Market Segmentation
Figure 11.2: Global Hematologic Malignancies Testing Market Research Methodology
Figure 11.3: Primary Research
Figure 11.4: Secondary Research
Figure 11.5: Data Triangulation
Figure 11.6: Bottom-Up Approach (Segment-Wise Analysis)
Figure 11.7: Top-Down Approach (Segment-Wise Analysis)
Figure 11.8: Assumptions and Limitations
Figure 11.9: Considered Factors for Data Prediction and Modelling
Figure 1: Impact Analysis on the Global Hematologic Malignancies Testing Market
Figure 2: Hematologic Malignancies Testing Market, By Product, 2018 vs. 2025 ($Million)
Figure 3: Hematologic Malignancies Testing Market, By Disease, 2018 vs. 2025 ($Million)
Figure 4: Hematologic Malignancies Testing Market, By End User, 2018 vs. 2025 ($Million)
Figure 5: Global Hematologic Malignancies Testing Market Snapshot
Figure 1.1: Global Hematologic Malignancies Testing Market, 2018-2025 ($Million)
Figure 2.1: Market Dynamics of Global Hematologic Malignancies Testing Market
Figure 2.2: Leukemia, U.S. Incident Rates per 100,000, 2006-2015
Figure 3.1: Share of Key Developments and Strategies, January 2016 – September 2019
Figure 3.2: Synergistic Activities Share (by Companies), January 2016 – September 2019
Figure 3.3: Approvals Share (by Companies), January 2016 – September 2019
Figure 3.4: Product Launches and Enhancements Share (by Companies), January 2016 – September 2019
Figure 3.5: Acquisition and Merger Share (by Companies), January 2016 – September 2019
Figure 3.6: Market Share Analysis for the Global Hematologic Malignancies Testing Market, 2018
Figure 3.7: Growth Share Matrix for Global Hematologic Malignancies Testing Market (by company), 2018
Figure 3.8: Growth Share Matrix for Global Hematologic Malignancies Testing Market (by region), 2018
Figure 3.9: Growth Share Matrix for Global Hematologic Malignancies Testing Market (by Product), 2018
Figure 3.10: Comprehensive Competitive Index, 2018 (by Region)
Figure 5.1: Global Hematologic Malignancies Testing Market (by Product), 2019 vs 2025
Figure 5.2: Hematologic Malignancies Testing Services Market, $Million, 2018-2025
Figure 5.3: Hematologic Malignancies Testing Kits Market, $Million, 2018-2025
Figure 5.4: Gene Panels Market, $Million, 2018-2025
Figure 5.5: Molecular Clonality Testing Market, $Million, 2018-2025
Figure 5.6: Translocation Testing Market, $Million, 2018-2025
Figure 5.7: Mutation Testing Market, $Million, 2018-2025
Figure 5.8: Minimal Residual Disease (MRD) Testing Market, $Million, 2018-2025
Figure 6.1: Global Hematologic Malignancies Testing Market (by Disease), 2019 vs 2025
Figure 6.2: Leukemia Testing Market, $Million, 2018-2025
Figure 6.3: Lymphoma Testing Market, $Million, 2018-2025
Figure 6.4: Multiple Myeloma Testing Market, $Million, 2018-2025
Figure 6.5: Myeloproliferative Neoplasms Testing Market, $Million, 2018-2025
Figure 6.6: Myelodysplastic Syndromes Testing Market, $Million, 2018-2025
Figure 7.1: Global Hematologic Malignancies Testing Market (by Technology), 2019 vs 2025
Figure 7.2: Hematologic Malignancies Testing Market by NGS, $Million, 2018-2025
Figure 7.3: Hematologic Malignancies Testing Market by PCR, $Million, 2018-2025
Figure 7.4: Hematologic Malignancies Testing Market by FISH, $Million, 2018-2025
Figure 7.5: Hematologic Malignancies Testing Market by Immunohistochemistry, $Million, 2018-2025
Figure 7.6: Hematologic Malignancies Testing Market by Flow Cytometry, $Million, 2018-2025
Figure 7.7: Hematologic Malignancies Testing Market by Other Technologies, $Million, 2018-2025
Figure 8.1: Global Hematologic Malignancies Testing Market (by End User), 2019 vs 2025
Figure 8.2: Specialty Clinics and Hospitals Market, $Million, 2018-2025
Figure 8.3: Diagnostic Laboratories Market, $Million, 2018-2025
Figure 8.4: Reference Laboratories Market, $Million, 2018-2025
Figure 8.5: Research Institutions Market, $Million, 2018-2025
Figure 9.1: Hematologic Malignancies Testing Market (by Region), $Million, 2019 and 2025
Figure 9.2: North America: Market Dynamics
Figure 9.3: North America Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.4: North America Hematologic Malignancies Testing Market (by Country), $Million, 2019 vs 2025
Figure 9.5: U.S. Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.6: Canada Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.7: Europe: Market Dynamics
Figure 9.8: Europe Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.9: Europe Hematologic Malignancies Testing Market (by Country), $Million, 2019 vs 2025
Figure 9.10: Germany Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.11: U.K. Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.12: France Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.13: Italy Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.14: Spain Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.15: Rest-of-Europe Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.16: Asia-Pacific: Market Dynamics
Figure 9.17: Asia-Pacific Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.18: Asia-Pacific Hematologic Malignancies Testing Market (by Country), $Million, 2019 vs 2025
Figure 9.19: China Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.20: Japan Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.21: India Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.22: Number of Death in India, by Leukemia (2010-2017)
Figure 9.23: Australia Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.24: Number of Death in Australia, by Leukemia (2010-2017)
Figure 9.25: Singapore Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.26: Rest-of-APAC Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.27: Rest-of-the-World: Market Dynamics
Figure 9.28: Rest-of-the-World Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.29: Rest-of-the-World Hematologic Malignancies Testing Market (by Country), $Million, 2019 vs 2025
Figure 9.30: Latin America Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.31: Middle East and Africa Hematologic Malignancies Testing Market, $Million, 2018-2025
Figure 9.32: Cancer Deaths in Saudi Arabia, By Type (2010-2016)
Figure 10.1: Total Number of Companies Profiled
Figure 10.2: Abbott Laboratories: Overall Product Portfolio
Figure 10.3: Abbott Laboratories: Overall Financials, 2016-2018
Figure 10.4: Abbott Laboratories: Revenue (by Segment), 2016-2018
Figure 10.5: Abbott Laboratories: Revenue Split for Diagnostics, 2016-2018
Figure 10.6: Abbott Laboratories: Revenue (by Region), 2016-2018
Figure 10.7: Abbott Laboratories: R&D Expenditure, 2016-2018
Figure 10.8: Abbott Laboratories: SWOT Analysis
Figure 10.9: Illumina, Inc.: Overall Product Portfolio
Figure 10.10: Illumina, Inc.: Overall Financials, 2016-2018
Figure 10.11: Illumina, Inc.: Revenue (by Segment), 2016-2018
Figure 10.12: Illumina, Inc.: Revenue (by Region), 2016-2018
Figure 10.13: Illumina, Inc.: R&D Expenditure, 2016-2018
Figure 10.14: Illumina, Inc.: SWOT Analysis
Figure 10.15: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
Figure 10.16: F. Hoffmann-La Roche Ltd: Overall Financials, 2016-2018
Figure 10.17: F. Hoffmann-La Roche Ltd: Sales (by Segment), 2016-2018
Figure 10.18: F. Hoffmann-La Roche Ltd: Sales (by Region), 2016-2018
Figure 10.19: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2016-2018
Figure 10.20: F. Hoffmann-La Roche: SWOT Analysis
Figure 10.21: Bio-Rad Laboratories, Inc.: Product Portfolio
Figure 10.22: Bio-Rad Laboratories, Inc.: Overall Financials, 2016-2018
Figure 10.23: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2016-2018
Figure 10.24: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2016-2018
Figure 10.25: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2016-2018
Figure 10.26: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 10.27: Sysmex Corporation: Overall Product Portfolio
Figure 10.28: Sysmex Corporation: Overall Financials, 2016-2018
Figure 10.29: Sysmex Corporation: Sales (by Segment), 2016-2018
Figure 10.30: Sysmex Corporation: Sales (by Region), 2016-2018
Figure 10.31: Sysmex Corporation: R&D Expenditure, 2016-2018
Figure 10.32: Sysmex Corporation: SWOT Analysis
Figure 10.33: ASURAGEN, INC.: Overall Product Portfolio
Figure 10.34: ASURAGEN, INC.: SWOT Analysis
Figure 10.35: Product Portfolio: Cancer Genetics Inc.
Figure 10.36: Cancer Genetics Inc.: Overall Financials, 2016-2018
Figure 10.37: Cancer Genetics Inc.: Sales (by Segment), 2016-2018
Figure 10.38: Cancer Genetics Inc.: Sales (by Region), 2016-2018
Figure 10.39: Cancer Genetics Inc.: R&D Expenditure, 2016-2018
Figure 10.40: Cancer Genetics Inc.: SWOT Analysis
Figure 10.41: QIAGEN N.V.: Overall Product Portfolio
Figure 10.42: QIAGEN N.V.: Overall Financials, 2016-2018
Figure 10.43: QIAGEN N.V.: Revenue (by Segment), 2016-2018
Figure 10.44: QIAGEN N.V.: Revenue (by Region), 2016-2018
Figure 10.45: QIAGEN N.V.: R&D Expenditure, 2016-2018
Figure 10.46: QIAGEN N.V.: SWOT Analysis
Figure 10.47: ArcherDX, Inc.: Overall Product Portfolio
Figure 10.48: ArcherDX, Inc.: SWOT Analysis
Figure 10.49: Adaptive Biotechnologies: Overall Product Portfolio
Figure 10.50: Adaptive Biotechnologies: SWOT Analysis
Figure 10.51: ICON plc: Overall Product Portfolio
Figure 10.52: ICON plc: Overall Financials, 2016-2018
Figure 10.53: ICON plc: Revenue (by Region), 2016-2018
Figure 10.54: ICON plc: SWOT Analysis
Figure 10.55: Quest Diagnostics Incorporated: Overall Product Portfolio
Figure 10.56: Quest Diagnostics Incorporated: Overall Financials, 2016-2018
Figure 10.57: Quest Diagnostics Incorporated: Revenue (by Business Segment), 2016-2018
Figure 10.58: Quest Diagnostics Incorporated: SWOT Analysis
Figure 10.59: ARUP Laboratories: Overall Product Portfolio
Figure 10.60: ARUP Laboratories: SWOT Analysis
Figure 10.61: Invivoscribe, Inc.: Overall Product Portfolio
Figure 10.62: Invivoscribe, Inc.: SWOT Analysis
Figure 10.63: NeoGenomics Laboratories, Inc.: Overall Product Portfolio
Figure 10.64: NeoGenomics Laboratories, Inc.: Overall Financials, 2016-2018
Figure 10.65: NeoGenomics Laboratories, Inc.: Revenue (by Segment), 2016-2018
Figure 10.66: NeoGenomics Laboratories, Inc.: R&D Expenditure, 2016-2018
Figure 10.67: NeoGenomics Laboratories, Inc.: SWOT Analysis
Figure 11.1: Global Hematologic Malignancies Testing Market Segmentation
Figure 11.2: Global Hematologic Malignancies Testing Market Research Methodology
Figure 11.3: Primary Research
Figure 11.4: Secondary Research
Figure 11.5: Data Triangulation
Figure 11.6: Bottom-Up Approach (Segment-Wise Analysis)
Figure 11.7: Top-Down Approach (Segment-Wise Analysis)
Figure 11.8: Assumptions and Limitations
Figure 11.9: Considered Factors for Data Prediction and Modelling
